Brazil Device Registration Transfers: What Must Move With the Holder?

Direct Answer: Only Registrations Transfer—Notified Devices Start Over

When an international medical device manufacturer restructures its Brazilian commercial footprint—whether by acquiring a local distributor, incorporating an independent corporate subsidiary, or terminating an agreement with an independent Brazilian Registration Holder (BRH or detentor)—it faces a strict procedural crossroad. In Brazil, an ANVISA device registration is not a private asset that can be simply assigned on paper. It is an administrative sanitary concession granted to a specific Brazilian legal entity under ANVISA RDC nº 903/2024, the regulatory framework that took effect on September 9, 2024.

The threshold determination for any portfolio transfer is regulatory regime classification under RDC nº 751/2022. Under RDC 903/2024 Article 27, medical devices subject to the legacy cadastro regime are legally equated to registered products (registro). Therefore, full administrative transfer of holder (transferência de titularidade) is legally available only for Class III and Class IV devices holding an active registro, as well as legacy cadastro files. Article 28 states that products subject to the notification regime (notificação) are not objects of a holder transfer, and the successor files a new notification or a new regularization, as applicable. Under RDC 751/2022 Articles 6 and 7, Class I and Class II devices are notified and Class III and Class IV devices are registered, so a current Class I or Class II notification is outside the transfer. Article 28 also excludes registration-exempt products. Article 8 of RDC 751/2022 excepts in vitro diagnostics from those classification rules; they follow RDC nº 830/2023.

For eligible Class III and Class IV devices, the legal transaction is executed through two paired, concomitant petitions submitted within a strict 180-calendar-day window: the successor (sucessora) petitions for the transfer of ownership, and the predecessor (sucedida) files the cancellation of the registration. Article 26 uses that name. ANVISA's transfer FAQ calls the same petition cancelamento de registro por transferência de titularidade. Under Article 6, from the effective date of the corporate or commercial operation, the successor is subrogated into the succeeded company's rights and obligations, including adaptation deadlines, sanitary rules, and restrictive measures on circulation. Article 29 keeps the product's characteristics and the registration's existing validity period, including the unexpired balance of the ten-year term in RDC 751/2022 Article 11. The number does not stay: the DOU publishes the new registration number and the cancellation of the old number together.

Why Leading English Guidance Is Outdated: RDC 102/2016 Is Revoked

Two English pages that still rank for Brazil holder transfers cite the revoked rule. Emergo by UL's Brazil registration-holder page still says RDC 102/2016 allows the transfer, that the previous holder must sign the transfer contract and ask ANVISA to cancel, and that ANVISA issues a new number while the original validity date carries over. Global Regulatory Partners' Brazil registration page likewise says a transfer to another holder is regulated by RDC 102/2016. The new-number and original-validity points match current Article 29. The governing citation is now RDC 903/2024.

On September 6, 2024, ANVISA's Collegiate Board enacted Resolução da Diretoria Colegiada - RDC nº 903/2024, published in the federal gazette (Diário Oficial da União - DOU) on September 9, 2024. Article 48 put the resolution into force on publication. Article 47 revoked RDC nº 102/2016, RDC nº 118/2016, RDC nº 233/2018, and article 13 of RDC nº 438/2020. Article 47 names each revoked resolution. The text is the consolidated rule for holder transfers across medicines, active pharmaceutical ingredients, cosmetics, sanitizers, foods, and medical devices (produtos para a saúde). It also covers updates to company authorizations and certificates, and the global transfer of clinical-trial responsibility.

Fukuma Advogados' note of September 9, 2024 describes RDC 903/2024 as a form revision from ANVISA's regulatory-stock review, without a change of merit, and says it did not change the procedures or deadlines in RDC 102/2016. That is why an older description of the 180-day window, the outgoing holder's participation, and the 90-day effectiveness of the specific resolutions can still be operationally useful. The petitions have to be anchored in RDC 903/2024. Where this article's device reading is more specific than that note, use the resolution text.

Transaction Triggers and What the Transfer May Not Alter

Under RDC 903/2024 Article 4, an application for transfer of registration titularidade must be anchored in one of two distinct transactional categories: corporate operations or commercial operations.

• Corporate Operations (Operações Societárias): Article 4 limits a corporate operation to cisão, fusão, or incorporação, under the Civil Code (Law nº 10.406/2002) and, subsidiarily, the Corporations Law (Law nº 6.404/1976). Those forms are mergers (fusão), incorporations (incorporação), spin-offs (cisão total ou parcial). A change of legal form is not on that list. Article 3 also leaves a razão social change that is unrelated to those operations outside this resolution.

• Commercial Operations (Operações Comerciais): An operation between companies that transfers assets, or a set of assets, without a cisão, fusão, or incorporação between them (Article 4, VII). A sale of a device portfolio from one Brazilian company to another is the usual example. The registration is not a private asset the contract assigns. The contract is the commercial operation that can start the ANVISA filing clock.

A holder transfer exists only when a different Brazilian legal entity becomes the detentor. A share purchase that leaves the same CNPJ on the concession is not, by itself, a transferência de titularidade under Articles 25 and 26. Article 1's sole paragraph does cover an operation carried out abroad when ANVISA's records have to be updated, including the certificate path in Article 12, paragraph 3. Confirm that the Brazilian CNPJ on the registration is actually changing before anyone starts the 180-day clock.

Regardless of transaction structure, the legal boundary of a titularidade transfer is absolute: the transfer petition cannot alter the technical-sanitary characteristics of the medical device. Article 2 limits the resolution to cases in which the technical-sanitary conditions and characteristics of the companies, the products, and any clinical trials are maintained. Article 4 defines those characteristics as the regular ANVISA status of the product, company, or trial immediately before the operation. Annex I requires both companies to declare that the previously approved characteristics have not changed and will not change until ANVISA authorizes the relevant act. A design, indication, or manufacturing change is not part of the transfer petition. Whether that change needs prior approval, may be implemented and then reported, or is not reportable is decided under RDC 751/2022, not by adding it to the transfer (alterações pós-registro).

Furthermore, incoming holders must evaluate the comprehensive scope of legal subrogation established by Article 6. From the transaction's effective date, the successor is fully subrogated into all regulatory rights, sanitary obligations, and legal liabilities previously held by the outgoing company. This statutory assumption includes:

• Compliance Deadlines: From the effective date of the operation, the successor takes on the succeeded company's adaptation deadlines and sanitary rules. For a device, that includes technovigilance duties the holder already had. The device holder keeps the technovigilance duties already attached to the concession.

• Sanitary Liability: The subrogation covers sanitary obligations already attached to the holder. It is not a separate list of complaint files or inspection responses beyond what the holder already owed.

• Enforcement Measures: Article 6 expressly includes restrictive measures already imposed on the circulation of the products.

graph TD
  A["Trigger: cisão, fusão, incorporação, or an asset transfer"] --> B{"Regime under RDC 751/2022"}
  B -->|"Class I or II notification"| C["Art. 28: not a holder transfer"]
  C --> D["Successor files a new notification. Outgoing holder cancels under RDC 751 Art. 29 only if it stops selling"]
  B -->|"Class III or IV registro, or legacy cadastro"| E["Arts. 25 to 27: transfer is available"]
  E --> F["Clock: junta arquivamento, or execution of the asset contract"]
  F --> G["Up to 180 days, both petitions together"]
  G --> H["Succeeded company files the cancellation and receives the Solicita token"]
  G --> I["Successor files the transfer with Art. 30 documents and the token"]
  H --> J["DOU publishes the new number and cancels the old number"]
  I --> J
  J --> K["Those resolutions take effect 90 days after publication, unless they say otherwise"]
  K --> L["Holder-data label text after petition approval. Stock rule is Art. 40"]

The Two Concomitant Petitions and the Strict 180-Day Clock

A fundamental design principle of Brazilian device concession governance is that transfer of ownership requires paired bilateral action. An incoming holder cannot petition ANVISA unilaterally. Under RDC 903/2024 Article 26, the transition requires two distinct petitions filed concomitantly:

1. Successor Petition (Petição da Empresa Sucessora): The incoming entity files the formal petition for Transfer of Registration Holder (Transferência de Titularidade de Registro).

2. Succeeded Entity Petition (Petição da Empresa Sucedida): The succeeded company files the cancellation petition. Article 26 calls it a cancellation of the registration. The transfer FAQ uses the longer name (Cancelamento de Registro por Transferência de Titularidade).

Both petitions must be protocolled concomitantly within 180 days. Article 26 does not call those days business days. Paragraph 2 sets the start:

• For Corporate Operations: Count from the date of arquivamento of the corporate act registered at the competent junta comercial (Junta Comercial).

• For Commercial Operations: Count from the date of execution of the contract that transfers assets, or a set of assets (instrumento contratual de transferência de ativos).

Article 26, paragraph 3, uses a different start when the holder is a Mercosul representative. The 180 days then run from the date the contract is formally interrupted between the Brazil-domiciled Mercosul representative that holds the Brazilian registration and the represented company that holds the registration in another Mercosul state. That start date is not the ordinary date of a distributor-to-subsidiary asset contract.

Article 26, paragraph 1, says a petition protocolled after those 180 days is denied. The paragraph ends at denial. It does not order a new initial registration, and it does not say the technical file is forfeited. Where the succeeded company still exists and still holds the registration, the concession can remain with that company. Where the corporate operation has extinguished that company, paragraph 1 does not state the consequence, and the parties need advice on that corporate fact before assuming a filing path.

Under RDC 903/2024 Article 30, the successor's transfer petition must be accompanied by four mandatory evidentiary components:

1. Official Petition Form: The standardized petition form (formulário de petição), completed and signed. Article 30 requires the signature and does not name the signatory. Annex I, which is a separate required document, is signed by the legal representative and the technical responsible (Responsável Técnico) of both the succeeded company and the successor.

2. Sanitary Fee Proof (TFVS): Proof of payment or statutory fee waiver for the Health Surveillance Inspection Fee (Taxa de Fiscalização e Vigilância Sanitária - TFVS), remitted via official Federal Collection Guide (Guia de Recolhimento da União - GRU).

3. Annex I Transaction Declaration: The formal Joint Declaration of Corporate or Commercial Operation (Declaração de Operação Societária ou Comercial). For a holder transfer, the successor lists each post-registration petition it wants ANVISA to keep analyzing, by protocol date, expediente number, and subject, and declares that every unlisted petition is withdrawn and will be closed under Article 32, sole paragraph. The legal representative and the technical responsible of each company sign. Both companies also declare that the previously approved technical-sanitary characteristics have not changed.

4. Updated Operating License: A valid copy of the successor's local sanitary license or permit (Licença de Funcionamento or Alvará Sanitário), issued by the competent municipal or state health surveillance authority (VISA), updated to reflect the company's current operational standing.

Filing in Sistema Solicita: The Electronic Token Choreography

Historically, titularidade transfers involved physical document submissions and complex notarized paper files. Since October 2021, ANVISA has fully digitized medical device transfer petitions through its proprietary electronic portal, Sistema Solicita. The October 2021 notice, which predates RDC 903/2024, is still the ANVISA description of the token. Confirm the current Solicita manual before filing, because the screen path can change. The notice limits transfers to processes that have already been published.

The operational filing sequence unfolds in four synchronized steps:

1. Step 1: Predecessor Filing: The outgoing registration holder logs into Sistema Solicita, locates the published device registration process number, and files the linked petition under the specific subject code for Cancellation by Transfer (Cancelamento por Transferência).

2. Step 2: Automated Token Generation: Upon formal protocol of the cancellation petition, Sistema Solicita automatically validates the process status and generates an exclusive alphanumeric security token. This token is delivered securely and directly into the outgoing holder's institutional ANVISA mailbox (Caixa Postal do Solicita).

3. Step 3: Bilateral Handshake: Under the commercial transfer contract, the outgoing holder provides the alphanumeric token to the incoming successor entity.

4. Step 4: Successor Protocol: The successor logs into Sistema Solicita to initiate the Transfer of Holder petition. The portal prompts the user to enter the active registration process number and the unique token. Once validated by the system, the token mechanically binds the two petitions in ANVISA's electronic docket, enabling the successor to upload the Article 30 evidentiary dossier.

Before this choreography can begin, the incoming successor entity must satisfy essential institutional prerequisites outlined on gov.br's official device transfer service portal:

• Corporate Database Registration: An active Brazilian National Taxpayer Registry (CNPJ) number, fully registered and in good standing within ANVISA's Company Database (Cadastro de Empresas).

• Digital Certificate Credentials: The service page requires a gov.br account at Silver (Prata) or Gold (Ouro).

• Designated Security Manager: A formally designated Security Manager (Gestor de Segurança) in order to access Solicita. The page tells that manager to sign in and file a petition linked to an existing process.

• Matching Company Authorizations (AFE): A valid federal Company Operating Authorization (Autorização de Funcionamento de Empresa - AFE) issued by ANVISA, explicitly covering the product category (medical devices / produtos para a saúde). The transfer FAQ says the successor can receive only products that match activities already authorized on its own AFE, and its example is medicines: a company authorized to import, distribute, and dispatch can hold registrations only for imported medicines. Do not read that example as an automatic summary denial of every device transfer that lacks an import AFE. Articles 7 to 10 are the device-relevant authorization rules: companies must petition AFE or Autorização Especial changes when the operation requires them; a new legal entity, or an existing one that is not yet regularized, starts with an initial grant; and cancellation of the succeeded company's AFE, when it applies, is filed within 30 days after publication of the transfer and cancellation resolutions and only after all of that company's registrations have been transferred.

Regarding regulatory expenses and review durations: The statutory TFVS fee varies according to the successor's official corporate revenue tier (Porte da Empresa). The device transfer service page, last modified on December 15, 2025, says the fee varies by company size and request type. It does not publish a transfer amount. The same page answers "how long does it take" with "not yet estimated." A separate stage time of about 10 minutes is the time to file the request, not an ANVISA decision time. Do not budget a review duration or a fee from a vendor quote.

What Moves With the Holder: Petitions, Dossiers, Stock, and Import Continuity

Navigating a transfer requires understanding the precise legal and operational boundary between what is inherited by the incoming holder, what is forfeited, and what liabilities remain with the predecessor.

Technical Dossier Custody and Holder Duties

Under RDC 751/2022 Article 4, Item VIII, the detentor is the public or private legal entity, manufacturer or importer, that is responsible for the device in Brazilian territory and holds the ANVISA commercialization grant. Article 56 requires an updated technical dossier (Dossiê Técnico). That article places the duty on the notification holder. Paragraph 1 says this dossier is not filed with the notification and stays with that holder. Paragraph 2 says it need not be a single physical or electronic file and may refer to other quality-system records, provided those records are available for inspection. Article 30's transfer list does not include a dossier handover. After Article 6 makes the successor the detentor, the successor needs the records that the holder duties already require.

Pending Petitions: Annex I Elections vs. Applications Under Analysis

The fate of ongoing regulatory petitions is strictly regulated under RDC 903/2024 Articles 31 and 32:

• Pending Post-Registration Petitions (Article 32): If the succeeded company has post-registration petitions that are awaiting analysis or have not yet been concluded, those petitions do not transfer automatically. Article 32 says they can pass to the successor only through the Annex I declaration of interest. The sole paragraph says petitions left off that list are a withdrawal by the successor and are closed by ANVISA. Annex I asks for the protocol date, expediente number, and subject, and the successor declares the withdrawal in the declaration itself.

• Applications Under Initial Review (Article 31): If a device registration application is still undergoing initial review by ANVISA and has not yet been published in the DOU, it cannot be transferred under RDC 903/2024. Transfer of titularidade applies strictly to published, active concessions. If a corporate or commercial transaction closes while an initial application is pending, the succeeded company must file an administrative amendment (aditamento) of the pending petition so the analysis can continue, and paragraph 2 says the succeeded company must present the Article 30 documents. This is not a holder transfer. The 2021 Solicita notice also says a transfer can be made only for a process that has already been published.

Import Continuity and Inventory Sell-Through Rules

Maintaining product supply during the transition period is addressed through specific transitional provisions in Articles 38 through 41:

• Import continuity (Articles 38 and 39): Article 38 allows the successor to import on the basis of the succeeded company's AFE until ANVISA decides on regularization of the company, provided the petition deadlines in this resolution were met. At clearance, the importer presents a copy of the Annex I operation declaration. Article 39 then assigns responsibility for the product and for remaining finished stock, including import, to the successor. Until the holder transfer is completed at ANVISA, those imports also need an authorizing declaration from the succeeded company, the signatory of the product's regularization petition. Paragraph 2 of Article 39 keeps the succeeded company jointly liable for acts practiced before the corporate or commercial operation.

• Finished Stock Depletion (Article 40): Commercial inventory manufactured prior to the effective date of the transfer resolution may continue to be imported and commercialized by the successor for a maximum period of 180 days after the specific cancellation and transfer resolutions take effect. The goods must have been produced before that effective date, and the new holder is the party that may import or sell them. Article 40 does not reset the registration term or authorize old packaging on later batches.

• Prohibition on Outdated Packaging (Article 41): In contrast to finished devices, raw packaging materials, labeling artwork, and Instructions for Use (IFU) bearing the predecessor's corporate identity or outdated registration number cannot be utilized for newly manufactured production batches once the transfer resolution becomes effective. Manufacturing facilities must transition to updated labeling artwork immediately upon the resolution's effective date.

Registration Numbers, Device Labeling, and the 90-Day Implementation Lag

The final phase of a Brazilian registration transfer centers on the simultaneous issuance of regulatory resolutions and the implementation of mandatory labeling modifications.

Under RDC 903/2024 Article 29, the formal approval of a transfer results in the simultaneous publication of two interconnected administrative acts in the DOU:

1. Cancellation Resolution: Publication of the cancellation of the old registration number. Article 29 requires that cancellation to be published with the new number. The Solicita notice refers to publication of the cancelamento por transferência).

2. New Concession Resolution: The same DOU publication gives the successor the new registration number. Article 29 keeps the product's characteristics and the existing validity period unchanged.

Article 11 of RDC 751/2022 makes a device registration valid for ten years from its publication in the DOU, with successive revalidation for the same period. Article 29 of RDC 903/2024 says the transfer leaves the product's characteristics and the validity period of the registration unchanged. The new number therefore does not start a new ten-year term.

A critical planning consideration is the 90-day implementation lag in Article 45. Unless a specific resolution says otherwise, the cancellation and transfer resolutions take effect 90 days after their publication. That gap is the clock for stock and for when old packaging can no longer be used on new batches. It is not an ERP or Siscomex rule, and it is not the same date as RDC 903/2024's own entry into force.

RDC 751/2022 Article 47 sets the label contents. Article 48 carries most of those contents into the instructions for use. RDC 903/2024 Article 33 is the separate limit on label and IFU text that changes because of a holder transfer. The label elements that matter for this event are:

• The legal manufacturer's company name and address, preceded by the word "manufacturer" or an equivalent symbol (Article 47, I).

• The notification or registration holder's company name and address (Article 47, II). Article 47 does not require the holder's CNPJ on the label.

• The notification or registration number, preceded by the ANVISA acronym (Article 47, XII). Article 47, XI, also requires the name of the legally qualified technical responsible on the label. Article 48, I, repeats the Article 47 information in the instructions for use except the lot or serial, the dates, and the technical responsible's name.

Because both the holder identity and the registration number change upon transfer, labeling updates are legally mandatory. However, Article 33 imposes two strict conditions: First, labeling and IFU adjustments may be implemented after ANVISA approves the transfer petition. The statutory verb is permissive: the changes may be implemented after approval, and paragraph 1 limits them to updating the holder's data. Do not treat publication in the DOU, or the Article 45 effective date, as the Article 33 trigger. The new number still has to appear on the label because Article 47, XII, requires it once that number exists. Article 33 does not authorize unrelated design, artwork, or claim changes.

Decision Matrix: Regulatory Regime x Operation Type x Required Filings

To assist market-access executives, corporate deal teams, and regulatory affairs directors in structuring transactions, the matrix below details the governing article, procedural route, filing deadlines, and operational impact across all device configurations.

Pre-Filing Verification Checklist: Five Critical Compliance Gates

Before executing corporate acquisition agreements or signing commercial transfer deeds, cross-functional teams should verify the following five regulatory gates:

1. Gate 1: Individual Product Regime Audit: Verify the exact regulatory status of every product SKU in ANVISA's official database. Never assume portfolio-wide transferability. Segregate Class III/IV registrations and legacy cadastros (eligible for RDC 903/2024 transfer) from Class I/II notifications (requiring fresh notification filings).

2. Gate 2: Successor Corporate Authorizations (AFE): Check the successor's AFE or Autorização Especial against Articles 7 to 10, and check the local licença de funcionamento or alvará that Article 30 requires. Match the authorized activities to the device role the successor will perform, whether that is manufacture, import, storage, or distribution. If the successor is a new legal entity, or is not yet regularized, Article 9 requires an initial grant rather than an alteration.

3. Gate 3: Foreign Legal Manufacturer Documentation: Article 30 does not require the foreign manufacturer's consent. A new notification does. For an imported device, Article 13 requires a legal-manufacturer declaration, consularized or apostilled, in Portuguese, English, or Spanish or with a sworn translation, no more than two years old when the document states no expiry, authorizing representation and commercialization in Brazil and attesting knowledge of the GMP requirements. Article 14 requires that kind of declaration on a new registration, plus a certificate of free sale or equivalent and a CBPF or proof that a CBPF was protocolled. Those documents belong to the new filing, not to the transfer attachment list.

4. Gate 4: Good Manufacturing Practice (CBPF) Custody: For Class III and Class IV devices, confirm the status of the manufacturing plant's Brazilian Good Manufacturing Practice certificate (Certificado de Boas Práticas de Fabricação - CBPF) or distribution and storage certificate (CBPDA) against Article 12. When a corporate or commercial operation leaves the previously examined technical-sanitary characteristics unchanged, the successor requests a cadastral update. That update is not a new certification, and the published validity period stays the same. The CBPF update is by production line and applies only when the operation involves the whole line. A switch of the Brazilian holder that does not move the foreign production line can fall outside paragraph 2, so confirm it before filing. Article 14 says an initial certification still under analysis is amended, not updated. Article 12 does not transfer an MDSAP report.

5. Gate 5: Physical Stock & Packaging Inventory Census: Conduct a physical audit of existing finished goods in Brazilian bonded warehouses, distributor pipelines, and transit shipments. Calculate label and IFU artwork lead times to ensure newly labeled production batches can be deployed before the 180-day stock depletion window expires.

Where This Guide Stops: Regulatory Boundaries and Scope Exclusions

This guide provides technical regulatory intelligence on ANVISA administrative filing procedures and must not be construed as legal advice for corporate structuring, tax planning, or contractual drafting. Brazilian contract law, antitrust review under the Administrative Council for Economic Defense (CADE), and customs regulations impose distinct requirements that require qualified Brazilian legal counsel.

In vitro diagnostic devices have their own classification resolution, RDC nº 830/2023. Article 2 of that resolution subjects IVDs to notification or registration according to their own risk rules. RDC 903/2024 can still supply the holder-transfer procedure, because it applies to products under sanitary surveillance, but the RDC 751/2022 Class I/II versus Class III/IV split does not decide an IVD. Read the IVD class off RDC 830/2023 before choosing a transfer or a new notification.

For comprehensive guidance on surrounding market-access decisions, explore our related analyses:

• Initial Submissions: For full initial registration requirements, dossier structures, and technical file formatting, review the Complete Brazil ANVISA Medical Device Registration Guide.

• Regulatory Cost Modeling: For statutory fee calculations, testing costs, and economic planning, consult the Brazil ANVISA Medical Device Cost Breakdown.

• Registration Holder Business Models: For strategic evaluation of independent BRH fee structures versus commercial distributor models, examine the Brazil Medical Device BRH Flat-Fee Pricing Guide.

• Quality Audits: For how ANVISA uses MDSAP in GMP inspections, which is separate from the Article 12 certificate-data update, read the MDSAP Medical Device Audit Guide.